Poster Session C

Poster Session C: Renal Cell Cancer
Trials in Progress Poster Session C: Renal Cell Cancer

Saturday, Feburary 16: 7:00 AM-7:55 AM and 12:30 AM-2:00 PM

Renal Cell Cancer: Poster Boards D1-K17

BOARD D1
Abstract 627: The UCLA Histo-Genetic Risk Classification (U-HGRC) to predict outcomes of localized clear cell renal cell carcinoma.
First Author: Cedric Lebacle, MD


BOARD D2
Abstract 541: TIVO-3: A phase III, randomized, controlled, multicenter, open-label study to compare tivozanib to sorafenib in subjects with refractory advanced renal cell carcinoma (RCC).
First Author: Brian Rini, MD, FACP


BOARD D3
Abstract 542: Safety and efficacy of nivolumab in metastatic renal cell carcinoma (mRCC): Final analysis from the NIVOREN GETUG AFU 26 study.
First Author: Laurence Albiges, MD, PhD


BOARD D4
Abstract 543: Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for locally advanced or metastatic renal cell carcinoma (mRCC): phase III KEYNOTE-426 study.
First Author: Thomas Powles, MD, PhD, FCRP


BOARD D5
Abstract 544: Subgroup analysis from JAVELIN Renal 101: Outcomes for avelumab plus axitinib (A + Ax) versus sunitinib (S) in advanced renal cell carcinoma (aRCC).
First Author: Toni Choueiri, MD


BOARD D6
Abstract 545: A phase II study investigating the safety and efficacy of savolitinib and durvalumab in metastatic papillary renal cancer (CALYPSO).
First Author: Thomas Powles, MD, PhD, FCRP


BOARD D7
Abstract 546: First-line pembrolizumab (pembro) monotherapy for advanced non-clear cell renal cell carcinoma (nccRCC): Results from KEYNOTE-427 cohort B.
First Author: David McDermott, MD


BOARD D8
Abstract 547: Thirty-month follow-up of the phase III CheckMate 214 trial of first-line nivolumab + ipilimumab (N+I) or sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC).
First Author: Nizar Tannir, MD, FACP


BOARD D9
Abstract 548: Results of a phase II study of atezolizumab and bevacizumab in non-clear cell renal cell carcinoma (nccRCC) and clear cell renal cell carcinoma with sarcomatoid differentiation (sccRCC).
First Author: Rana McKay, MD


BOARD D10
Abstract 549: CB-839, a glutaminase inhibitor, in combination with cabozantinib in patients with clear cell and papillary metastatic renal cell cancer (mRCC): Results of a phase I study.
First Author: Funda Meric-Bernstam, MD


BOARD D11
Abstract 550: Analysis of overall survival (OS) based on early tumor shrinkage in the phase III METEOR study of cabozantinib (cabo) versus everolimus (eve) in advanced renal cell carcinoma (RCC).
First Author: Ignacio Duran, MD, PhD


BOARD D12
Abstract 551: Alterations in DNA damage repair (DDR) genes and outcomes to systemic therapy in 225 immune-oncology (IO) versus tyrosine kinase inhibitor (TKI) treated metastatic clear cell renal cell carcinoma (mccRCC) patients (pts).
First Author: Yasser Ged, MBBS, MRCP


BOARD D13
Abstract 552: Novel predictive models of early death less than one year in patients with metastatic RCC treated with first-line tyrosine kinase inhibitors.
First Author: Minyong Kang


BOARD D14
Abstract 553: Genomic analysis of mitochondrial mutations in chromophobe renal cell carcinoma by using low-depth whole genome sequencing.
First Author: Minyong Kang


BOARD D15
Abstract 554: Thick perirenal fat predicts the growth pattern of renal cell carcinoma.
First Author: Eiji Kashiwagi, MD, PhD


BOARD D16
Abstract 555: Axitinib versus sunitinib as first-line therapies for metastatic renal cell carcinoma: A multicenter retrospective analysis.
First Author: Shingo Hatakeyama, MD


BOARD D17
Abstract 556: Impact of disagreement between the IMDC and MSKCC risk groups on prognosis in patients with metastatic renal cell carcinoma.
First Author: Shingo Hatakeyama, MD


BOARD D18
Abstract 557: Modeling of prognostication and differential genomic expression in the tumor microenvironment of clear cell renal cell carcinoma.
First Author: Sunyoung Lee, MD, PhD


BOARD D19
Abstract 558: Results from a phase I expansion cohort of the first-in-class oral HIF-2α inhibitor PT2385 in combination with nivolumab in patients with previously treated advanced RCC.
First Author: Brian Rini, MD, FACP


BOARD D20
Abstract 559: Treatment utilization trends and outcomes in renal liposarcoma (RLS): A National Cancer Database (NCDB) analysis.
First Author: Midhun Malla, MD


BOARD D21
Abstract 560: Sporadic angiomyolipomas (AMLs) growth kinetics while on everolimus (SAGE).
First Author: Daniel Geynisman, MD


BOARD D22
Abstract 561: A phase I/II trial of pazopanib alternating with bevacizumab in treatment-naïve metastatic clear cell renal cell carcinoma (CCRCC) patients: Phase I results.
First Author: Saby George, MD, FACP


BOARD E1
Abstract 562: Efficacy and safety of nivolumab in patients with non-clear cell renal cell carcinoma (RCC): Results from the phase IIIb/IV CheckMate 374 study.
First Author: Nicholas Vogelzang, MD, FASCO, FACP


BOARD E2
Abstract 563: Evolving patterns of metastatic renal cell carcinoma: A meta-analysis.
First Author: Justin Lin, None


BOARD E3
Abstract 564: Treatment-free survival (TFS) after discontinuation of first-line nivolumab (NIVO) plus ipilimumab (IPI) or sunitinib (SUN) in intention-to-treat (ITT) and IMDC favorable-risk patients (pts) with advanced renal cell carcinoma (aRCC) from CheckMate 214.
First Author: David McDermott, MD


BOARD E4
Abstract 565: Real-world use of sorafenib for advanced renal cell carcinoma patients with cardiovascular disease: Nationwide survey in Japan.
First Author: Teruo Inamoto, MD, PhD


BOARD E5
Abstract 566: Impact of body mass index (BMI) on treatment outcomes to immune checkpoint blockade (ICB) in metastatic renal cell carcinoma (mRCC).
First Author: Aly-Khan Lalani, MD, FRCPC


BOARD E6
Abstract 567: The effect of loss of SETD2 on mitochondrial dysfunction in clear cell renal cell carcinoma.
First Author: Robert Hapke, None


BOARD E7
Abstract 568: Efficacy of targeted therapy (TT) after checkpoint inhibitors (CPI) in metastatic renal cell carcinoma (mRCC): Results from the Canadian Kidney Cancer Information System (CKCis).
First Author: Austin Kalirai


BOARD E8
Abstract 569: Systematic review and REMARK scoring of renal cell carcinoma (RCC) prognostic circulating biomarker manuscripts.
First Author: Marco Iafolla, MD


BOARD E9
Abstract 570: Is cytoreductive nephrectomy necessary in metastatic renal cell carcinoma with primary kidney tumor in situ treated by sunitinib: Real-world data from a single Chinese center.
First Author: Wen-Hao Xu


BOARD E10
Abstract 571: Elevated CD36 expression correlates with increased visceral adipose tissue and predicts poor prognosis in ccRCC patients.
First Author: Wen-Hao Xu


BOARD E11
Abstract 572: Prognostic impact of neutrophil-to-lymphocyte ratio in renal cell carcinoma: A systematic review and meta-analysis.
First Author: Veronica Mollica, MD


BOARD E12
Abstract 573: Real-world clinical outcomes of pazopanib immediately following immunotherapy discontinuation for the treatment of advanced renal cell carcinoma.
First Author: Xiting Cao, PhD


BOARD E13
Abstract 574: Exploratory endpoints in a FARETES study of the efficacy of testosterone in metastatic renal cell carcinoma (mRCC) patients.
First Author: Ilya Tsimafeyeu, MD


BOARD E14
Abstract 575: Outcomes of patients with metastatic clear cell renal cell carcinoma treated with second-line VEGFR-TKI after first-line immune checkpoint inhibitors.
First Author: Amishi Shah, MD


BOARD E15
Abstract 576: Impact of treatment and insurance on socioeconomic disparities on the survival of renal cancer patients in Thailand.
First Author: Phichai Chansriwong, MD


BOARD E16
Abstract 577: Concordance between PD-L1 assays for metastatic renal cell carcinoma (mRCC) and metastatic urothelial carcinoma (mUC).
First Author: Jason Zhu, MD


BOARD E17
Abstract 578: A phase II study of cabozantinib as first-line treatment in metastatic collecting ducts carcinoma: The BONSAI trial.
First Author: Giuseppe Procopio, MD


BOARD E19
Abstract 580: Receipt of systemic therapy in older versus younger patients (pts) with metastatic renal cell carcinoma (mRCC).
First Author: Andrew Hahn, MD


BOARD E20
Abstract 581: Outcomes in patients (pts) with advanced renal cell carcinoma (aRCC) who discontinued (DC) first-line nivolumab + ipilimumab (N+I) or sunitinib (S) due to treatment-related adverse events (TRAEs) in CheckMate 214.
First Author: Nizar Tannir, MD, FACP


BOARD E21
Abstract 582: Are immune checkpoint inhibitors (ICI) a valid option for papillary renal cell carcinoma (pRCC)? A multicenter retrospective study.
First Author: Manon De Vries-Brilland, MSc


BOARD E22
Abstract 583: RNAseq in addition to next generation sequencing in advanced genitourinary cancers reveals transcriptomic silencing of DNA mutations: Implications for resistance to targeted therapeutics.
First Author: Jacob Adashek, BA


BOARD F1
Abstract 584: First-line (1L) immuno-oncology (IO) combination therapies in metastatic renal cell carcinoma (mRCC): Preliminary results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).
First Author: Shaan Dudani, MBChB


BOARD F2
Abstract 585: Sites of metastasis (mets) and association with clinical outcomes (CO) in metastatic renal cell carcinoma (mRCC) patients (pts) treated with cabozantinib (cabo).
First Author: Dylan Martini, BA


BOARD F3
Abstract 586: Angiogenic factor and cytokine analysis among patients with renal cell carcinoma treated with adjuvant VEGFR TKIs.
First Author: Wenxin Xu, MD


BOARD F4
Abstract 587: Neoadjuvant durvalumab +/- tremelimumab affects the expression of immune checkpoint (IC) molecules on myeloid derived suppressor cells (MDSC) in patients (pts) with locally advanced renal cell carcinoma (RCC).
First Author: Jaleh Fallah, MD


BOARD F5
Abstract 588: Eficacy and safety of first-line TKI in elderly with metastatic renal cancer.
First Author: Luciana Leite, MD


BOARD F6
Abstract 589: Characterization of tumor mutational burden (TMB), PD-L1, and DNA repair genes to assess correlation with immune checkpoint inhibitors (ICIs) response in metastatic renal cell carcinoma (mRCC).
First Author: Matthew Labriola, MD


BOARD F7
Abstract 590: Efficacy of alpha-1,3-galactosyltransferase-expressing allogeneic renal cell carcinoma immunotherapy in patients (pts) with refractory metastatic renal cell carcinoma (mRCC).
First Author: Andrew Hahn, MD


BOARD F8
Abstract 591: Expectations of cure among patients with advanced genitourinary cancer treated with immunotherapy.
First Author: Cristiane Bergerot, PhD, MS, BS


BOARD F9
Abstract 592: The significance of insulin receptor expression to predict the resistance to VEGFR-TKIs and induce PD-L1 expression in advanced clear cell renal cell carcinoma.
First Author: Masayuki Takahashi, MD


BOARD F10
Abstract 593: Synchronous and metachronous cases of renal cell carcinoma and hematologic malignancies in a state cancer registry.
First Author: John Henegan, MD


BOARD F11
Abstract 594: Investigation of IMPDH2 overexpression in renal cell carcinoma (RCC) & its association with oncologic outcomes.
First Author: Arun Sendilnathan, MD


BOARD F12
Abstract 595: Disparities in survival outcomes in African Americans in renal cell carcinoma: Impact of oncological versus nononcological factors.
First Author: Margaret Meagher, BA


BOARD F13
Abstract 596: Association of elevated C-reactive protein with oncologic outcomes in renal CELL carcinoma: A multicenter analysis.
First Author: Sunil Patel, MD


BOARD F14
Abstract 597: Development and validation of a novel scoring index (C-reactive protein, age, race, and tumor size) to predict renal functional decline post partial nephrectomy.
First Author: Margaret Meagher, BA


BOARD F15
Abstract 598: Clinical predictors of sarcomatoid kidney cancer: The results of a UCLA and french UroCCR network collaboration.
First Author: Cedric Lebacle


BOARD F16
Abstract 599: Outcomes of stereotactic ablative radiotherapy for extra-cranial oligo-metastatic renal cell cancer.
First Author: Yuanyuan Zhang, MD, PhD


BOARD F17
Abstract 600: Pembrolizumab (pembro) and cabozantinib (cabo) in patients (pts) with metastatic renal cell carcinoma (mRCC): Phase I results.
First Author: Molika Keeler, MS


BOARD F18
Abstract 601: The prognostic value of glycosylphosphatidylinositol-anchored 80 kD protein (GPI-80) positive myeloid derived suppressor cells (MDSCs) in peripheral blood of metastatic renal cell carcinoma (mRCC) patients.
First Author: Tomoyuki Kato, MD


BOARD F19
Abstract 602: Comparison of retroperitoneal and transperitoneal robotic partial nephrectomy by pentafecta perioperative and renal functional outcomes.
First Author: Chang Il Choi, MD


BOARD F20
Abstract 603: Prognostic role of PD-L1 expression in patients with advanced renal cell carcinoma (RCC) treated with sunitinib.
First Author: Clara Iglesias, MD


BOARD F21
Abstract 604: Postoperative long-term prognosis of localized renal cell carcinoma after partial or radical nephrectomy: Analysis of cancer metastasis and deaths during a more than five-year follow-up.
First Author: Sang Hyun Park, MD


BOARD F22
Abstract 605: Patterns of response of organ specific metastasis in patients with metastatic renal cell cancer (mRCC) treated with an immune checkpoint inhibitor (CPI) post tyrosine kinase inhibitor (TKI).
First Author: Sarah Picardo, MBBCh, PhD


BOARD G1
Abstract 606: Real-world experience with sunitinib treatment in patients with metastatic renal cell carcinoma: Clinical outcome according to risk score.
First Author: Manuela Schmidinger, MD


BOARD G2
Abstract 607: Evaluation of tumor microenvironment and biomarkers of immune checkpoint inhibitor (ICI) response in metastatic renal cell carcinoma (mRCC).
First Author: Jason Zhu, MD


BOARD G3
Abstract 608: The association of rising serum uric acid levels with survival in renal cell carcinoma.
First Author: Kendrick Yim


BOARD G4
Abstract 609: The association between hospitals’ risk-adjusted emergency department visits and survival and costs in kidney cancer patients.
First Author: Joel Segel, PhD


BOARD G5
Abstract 610: Real-world assessment of clinical outcomes among first-line (1L) sunitinib (SUN) patients (pts) with metastatic renal cell carcinoma (mRCC) by the international mRCC database consortium (IMDC) risk group.
First Author: Marie-France Savard, FRCP, MD


BOARD G6
Abstract 611: PAzopanib as first line in MEtastatic RCC patients: A “real-world” ITalian experience (PAMERIT study)—Preliminary results.
First Author: Alessandra Mosca, MD, PhD


BOARD G7
Abstract 612: Association of inflammation and clinical outcomes (CO) in metastatic renal cell carcinoma (mRCC) patients (pts) treated with cabozantinib (cabo).
First Author: Dylan Martini, BA


BOARD G8
Abstract 613: Body mass index (BMI) and toxicities and association with clinical outcomes (CO) in metastatic renal cell carcinoma (mRCC) patients (pts) treated with cabozantinib (cabo).
First Author: Dylan Martini, BA


BOARD G9
Abstract 614: Angiogenic and immunomodulatory biomarkers in axitinib-treated patients (pts) with advanced renal cell carcinoma (aRCC).
First Author: Brian Rini, MD, FACP


BOARD G10
Abstract 615: Fecal microbiota transplantation for TKI-induced diarrhea in patients with metastatic renal cell carcinoma.
First Author: Ernesto Rossi, MD


BOARD G11
Abstract 616: A prospective phase II trial of gemcitabine plus axitinib in patients with sarcomatoid type renal carcinoma.
First Author: Inkeun Park, MD, PhD


BOARD G12
Abstract 617: The association of anxiety and depression with mortality risk among patients with clear cell renal cell carcinoma undergoing nephrectomy.
First Author: Vignesh Packiam, MD


BOARD G13
Abstract 618: Proposal for tripartite re-classification of T1 renal cell carcinoma into cT1a (very low risk), cT1b (low risk), and cT1c (intermediate risk) substages.
First Author: Aaron Bradshaw, BS


BOARD G14
Abstract 619: Safety and feasibility of nephrectomy after receipt of immune checkpoint inhibitors for renal cell carcinoma.
First Author: Nirmish Singla, MD


BOARD G15
Abstract 620: Fumarate hydratase expression in localized, radically-resected clear cell renal cell carcinoma and its association with clinical outcomes.
First Author: Giovanni FucÃ


BOARD G16
Abstract 621: The role of radiomics in the preoperative diagnosis of renal cell carcinoma with sarcomatoid dedifferentiation (sRCC).
First Author: Chalairat Suk-Ouichai, MD


BOARD G17
Abstract 622: Duration of treatment (DOT) with targeted therapies (TT) or immunotherapy (IO) in PBRM1 mutated metastatic renal cell carcinoma (mRCC).
First Author: Nazli Dizman, MD


BOARD G18
Abstract 623: Prognostic value of gain of chromosome 5q in localized renal cell carcinoma.
First Author: Cedric Lebacle


BOARD G19
Abstract 624: Nivolumab in second or third line setting for the treatment of metastatic renal cell carcinoma (mRCC): The real-world experience from Guy’s Hospital.
First Author: Ha Mo Linh Le, MD


BOARD G20
Abstract 625: Radiomic correlates of molecular and clinicopathological characteristics in clear cell renal cell carcinoma.
First Author: Heidi Coy, BS


BOARD G21
Abstract 626: Prognostic value of loss of chromosome 10q in patients with localized renal cell carcinoma.
First Author: Cedric Lebacle


BOARD H1
Abstract 628: Are patients ready to participate in diet intervention trials in oncology? Experience from renal cell carcinoma (RCC) patients.
First Author: Emeline Colomba


BOARD H2
Abstract 629: Improving the definition of high-risk patients for tumor recurrence from clear cell renal cell carcinoma: The U-CISS classification.
First Author: Cedric Lebacle


BOARD H3
Abstract 630: Combination anti-angiogenic tyrosine kinase inhibition and anti-PD1 immunotherapy in metastatic renal cell carcinoma: A retrospective analysis of safety, tolerance, and clinical outcomes.
First Author: Andrew Laccetti, MD, MS


BOARD H4
Abstract 631: Identifying predictive biomarkers for metastatic progression in stage I and II clear cell renal cell carcinoma.
First Author: Neal Murphy, MD


BOARD H5
Abstract 632: The role of architectural patterns and cytologic features in the prognosis of clear cell renal cell carcinoma.
First Author: Qi Cai, MD


BOARD H6
Abstract 633: Comprehensive molecular and genomic characterization of pancreatic tropism in metastatic renal cell carcinoma.
First Author: Nirmish Singla, MD


BOARD H7
Abstract 634: Adiponectin-AdipoR1 axis in renal cell carcinoma plays a pivotal role in tumor progression and drug resistance.
First Author: Guangxi Sun, PhD


BOARD H8
Abstract 635: Does increasing time to surgery affect survival in stage I renal cell carcinoma? Analysis of the national cancer database.
First Author: Brittney Cotta, MD


BOARD H9
Abstract 636: Prevalence, disease-free (DFS) and overall (OS) survival of contemporary high-risk renal cell carcinoma (RCC) patients eligible for adjuvant checkpoint inhibitor trials: A RECUR database analysis.
First Author: Saeed Dabestani


BOARD H10
Abstract 637: Direct impact of clinical research in metastatic renal cell carcinoma (mRCC): A cost-effectiveness analysis of patient care outcomes and cost savings in a real-life scenario of a large public university hospital in Spain.
First Author: Silvia Garcia-Garro


BOARD H12
Abstract 639: The association of NOX4 mediated nuclear colocalization and overall survival in renal cell carcinoma.
First Author: Dharam Kaushik, MD


BOARD H13
Abstract 640: Molecular stratification of high-grade unclassified renal cell carcinoma to improve prognostication and management strategy.
First Author: Ying-Bei Chen, MD, PhD


BOARD H14
Abstract 641: Genomic biomarkers of response to nivolumab/ipilimumab (nivo/ipi) and nivolumab (nivo) monotherapy in 108 patients with advanced renal cell carcinoma.
First Author: Chung-Han Lee, MD, PhD


BOARD H15
Abstract 642: Patients’ perspective of quality-of-life issues in a randomized study in open surgery of patients with renal cell carcinoma.
First Author: Britt-Inger Kroger Dahlin, RN


BOARD H16
Abstract 643: The mutational burden of targeted genes significantly correlated with overall survival after targeted therapy in metastatic renal cell carcinoma.
First Author: Jae Young Joung, MD


BOARD H17
Abstract 644: Influence of access on survival of renal cancer in a Brazilian center.
First Author: Luciana Leite, MD


BOARD H18
Abstract 645: Immune-related adverse events are associated with improved outcomes in ICI-treated renal cell carcinoma patients.
First Author: Roy Elias, MD


BOARD H19
Abstract 646: Results of a phase II study to evaluate the safety and efficacy of RX-0201 in combination with everolimus in subjects with metastatic renal cell carcinoma (mRCC).
First Author: Neeraj Agarwal, MD


BOARD H20
Abstract 647: Prognostic and predictive role of comprehensive geriatric assessment (CGA) in elderly patients with metastatic renal cell cancer (RCC) treated with sunitinib (SUN) or pazopanib (PAZ): A single center experience.
First Author: Francesco Pierantoni


BOARD J1
Abstract 648: Treatment disparities among patients in the National Cancer Database (NCDB) with clinical TIa and TIb renal masses.
First Author: Joshua Sterling, MD


BOARD J2
Abstract 649: Effect of immunotherapy (IO) on primary renal tumor in metastatic renal cell cancer (mRCC).
First Author: Antoine Jamet, MS


BOARD J3
Abstract 650: Sunitinib for metastatic renal cell carcinoma: A systematic review and meta analysis of real world and clinical trials data.
First Author: Michael Moran, MD, PhD, MRCS


BOARD J4
Abstract 651: Leveraging a robust patient-derived xenograft platform to characterize predictors for engraftment and oncologic outcomes in renal cell carcinoma patients.
First Author: Nirmish Singla, MD


BOARD J5
Abstract 652: Safety and efficacy of restarting immune checkpoint inhibitors (CPI) after immune-related adverse events (irAEs) in metastatic renal cell carcinoma (mRCC).
First Author: Sarah Abou Alaiwi, MD


BOARD J6
Abstract 653: Safety and efficacy of immune checkpoint inhibitors (CPI) in metastatic renal cell cancer (RCC) and urothelial cancer (UC) patients (pts) with pre-existing autoimmune disorders (AD).
First Author: Nieves Martinez Chanza, ABFT


BOARD J7
Abstract 654: Relation between clinicopathological findings and PD-1 or PD-L1 status in non-clear cell renal cell carcinoma by a multicenter study.
First Author: Hiroaki Matsumoto, MD, PhD


BOARD J8
Abstract 655: Cell-free DNA analysis in renal cell carcinoma: Comparison with tumor sequencing and correlation with response to therapy.
First Author: Lana Hamieh, MD


BOARD J9
Abstract 656: A multigene expression score for predicting response to anti-PD-1/PD-L1 therapy for clear cell renal cell cancer patients.
First Author: Yukti Choudhury, PhD


BOARD J10
Abstract 657: Overall responses with coordinated pembrolizumab and high dose IL-2 (5-in-a-row schedule) for therapy of metastatic clear cell renal cancer: A single center, single arm trial.
First Author: Jonathan Chatzkel, MD


BOARD J11
Abstract 658: Patient perspectives on cytoreductive nephrectomy after CARMENA.
First Author: Dena Battle, BS


BOARD J12
Abstract 659: Clinical activity of ipilimumab plus nivolumab (Ipi/Nivo) in patients (pts) with metastatic non-clear cell renal cell carcinoma (nccRCC).
First Author: Ruby Gupta, MD


BOARD J13
Abstract 660: Preliminary results of phase I clinical trial of high doses of seleno-L-methionine (SLM) in sequential combination with axitinib in previously treated and relapsed clear cell renal cell carcinoma (ccRCC) patients.
First Author: Rohan Garje, MD


BOARD J14
Abstract 661: Associations of rurality and disease outcomes in urologic malignancies.
First Author: Alejandro Abello, MD


BOARD J15
Abstract 662: Mechanisms underlying the association between sarcopenia and poor oncologic outcomes in clear cell renal cell carcinoma.
First Author: Alejandro Sanchez, MD


BOARD J16
Abstract 663: Assessment of intratumor heterogeneity using imaging texture features in clear cell renal cell carcinoma.
First Author: Durga Udayakumar, PhD


BOARD J17
Abstract 664: Genomic and clinical determinants of recurrence in localized clear cell renal cell carcinoma (ccRCC).
First Author: Ziad Bakouny, MD, MD, MD, MSc, MSc


BOARD J18
Abstract 665: Tobacco as a possible prognostic factor in advanced renal cell carcinoma.
First Author: Maria Pilar Solis-Hernandez, MD


BOARD J19
Abstract 666: The impact of PBRM1 mutations on overall survival in greater than 2,100 patients treated with immune checkpoint blockade (ICB).
First Author: A. Hakimi, MD


BOARD J20
Abstract 667: Effects of sunitinib and pazopanib on patients physical, social, and emotional function: Result of a prospective patients reported outcome tool.
First Author: Prantik Das, MD


BOARD J21
Abstract 668: Real-world outcomes of genetic testing in a GU genetics clinic and evaluation of current guidelines.
First Author: Annelise Pace, MS


BOARD J22
Abstract 669: Ipilimumab plus nivolumab (Ipi/Nivo) as salvage therapy in patients with immunotherapy (IO)-refractory metastatic renal cell carcinoma (mRCC).
First Author: Anita Gul, MD


BOARD K1
Abstract 670: Dichotomous sized-based clinical staging of localized renal masses affects management but not clinical outcomes.
First Author: Lael Reinstatler, MD, MPH


BOARD K2
Abstract 671: Analysis of toxicity and clinical outcomes (CO) in full versus reduced dose cabozantinib (cabo) in metastatic renal cell carcinoma (mRCC) patients (pts).
First Author: Dylan Martini, BA


BOARD K3
Abstract 672: Factors linked with receiving a lymph node dissection during surgery for nonmetastatic renal cell carcinoma.
First Author: Kushan Radadia, MD


BOARD K4
Abstract 673: Rates of occult brain metastases in patients (pts) with advanced renal cell carcinoma (RCC): A cohort study from patients treated across 22 clinical trials.
First Author: Ritesh Kotecha, MD


BOARD K5
Abstract 674: Sarcopenia is independently associated with decreased overall survival after surgery for inferior vena cava tumor thrombus patients.
First Author: Milton Williams


BOARD K6
Abstract 675: The genomic landscape of metastatic clear cell renal cell carcinoma (ccRCC) after treatment with systemic therapy.
First Author: Johannes Van Der Mijn, MD, PhD


BOARD K7
Abstract 676: Positive surgical margins after radical nephrectomy for localized kidney cancer: Impact on survival.
First Author: Stephen Ryan, MD


BOARD K8
Abstract TPS677: Phase II trial of nivolumab (nivo) plus ipilimumab (ipi) in patients with SMARCB1-deficient kidney malignancies.
First Author: Pavlos Msaouel, MD, PhD


BOARD K9
Abstract TPS678: Phase II trial of ixazomib combined with gemcitabine and doxorubicin in patients with SMARCB1-deficient kidney malignancies.
First Author: Pavlos Msaouel, MD, PhD


BOARD K10
Abstract TPS679: Randomized phase II trial of intravenous ascorbic acid (AA) as an adjunct to pazopanib for metastatic and unresectable clear cell renal cell carcinoma (ccRCC): A study of Academic and Community Cancer Research United (ACCRU) GU1703.
First Author: Niraj Shenoy, MD, MS


BOARD K11
Abstract TPS680: An open-label phase II study to evaluate PT2977 for the treatment of von Hippel-Lindau disease-associated renal cell carcinoma.
First Author: Eric Jonasch, MD


BOARD K12
Abstract TPS681: RENAVIV: A randomized phase III, double-blind, placebo-controlled study of pazopanib with or without abexinostat in patients with locally advanced or metastatic renal cell carcinoma.
First Author: Rahul Aggarwal, MD


BOARD K13
Abstract TPS682: CANTATA: Randomized, international, double-blind study of CB-839 plus cabozantinib versus cabozantinib plus placebo in patients with metastatic renal cell carcinoma.
First Author: Nizar Tannir, MD, FACP


BOARD K14
Abstract TPS683: Phase Ib (COSMIC-021) trial of cabozantinib (C) in urothelial carcinoma (UC) or C in combination with atezolizumab (A) in patients (pts) with UC, castrate resistant prostate cancer (CRPC) or renal cell carcinoma (RCC).
First Author: Sumanta Pal, MD


BOARD K15
Abstract TPS684: PROSPER: A phase III randomized study comparing perioperative nivolumab (nivo) versus observation in patients with localized renal cell carcinoma (RCC) undergoing nephrectomy (ECOG-ACRIN 8143).
First Author: Lauren Harshman, MD


BOARD K16
Abstract TPS685: A phase II open-label study of cabozantinib in patients with advanced or unresectable renal cell carcinoma pretreated with one immune-checkpoint inhibitor: The BREAKPOINT trial.
First Author: Elena Verzoni, MD, MD


BOARD K17
Abstract TPS686: Phase II study of sitravatinib in combination with nivolumab in patients undergoing nephrectomy for locally-advanced clear cell renal cell carcinoma (ccRCC).
First Author: Jose Karam, MD